Conference
Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
Authors
Trudel S; McCurdy A; Fu M; Sutherland HJ; Louzada ML; Chu MP; White DJ; Mian HS; Kotb R; Othman I
Volume
140
Pagination
pp. 7306-7307
Publisher
American Society of Hematology
Publication Date
November 15, 2022
DOI
10.1182/blood-2022-160445
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971